Cyclerion to Participate at Upcoming September 2020 Investor Conferences
Cyclerion Therapeutics (Nasdaq: CYCN), a clinical-stage biopharmaceutical company, announced its participation in several investor conferences in September 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cyclerion Therapeutics (Nasdaq: CYCN), a clinical-stage biopharmaceutical company, announced its participation in several investor conferences in September 2020. Key events include the Citi’s 15th Annual BioPharma Virtual Conference on September 9th, H.C. Wainwright's 22nd Annual Global Investment Conference on September 16th, and the Cantor Virtual Global Healthcare Conference on September 16th and 17th. Additionally, Cyclerion will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21st. Webcasts of presentations will be accessible via Cyclerion's website for 90 days.
Details
News Market Reaction – CYCN
The recorded move for CYCN in the trading session of this news was -2.04%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that Company management will be participating in several upcoming September 2020 investor conferences:
- Citi’s 15th Annual BioPharma Virtual Conference on September 9th
- H.C. Wainwright & Co 22nd Annual Global Investment Conference on September 16th at 9:30 a.m. ET
- Cantor Virtual Global Healthcare Conference on September 16th and a virtual Fireside Chat on September 17th at 3:20 p.m. ET
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21st –23rd on September 21st at 10:50 a.m. ET
A live webcast of the H.C. Wainwright, Cantor, and Oppenheimer presentations can be accessed within the Investors & Media section of the Cyclerion.com website. An archived replay of the webcast will be available for approximately 90 days following the presentation.
About Cyclerion Therapeutics
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Lead programs include its vascular-targeted olinciguat in Phase 2 development for sickle cell disease and IW-6463, a pioneering CNS-penetrant sGC stimulator in clinical development for Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Alzheimer's Disease with Vascular pathology (ADv)
For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).
Investors
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.